Last reviewed · How we verify
CAR-GPRC5D
At a glance
| Generic name | CAR-GPRC5D |
|---|---|
| Sponsor | Nanjing IASO Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma (NA)
- A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) (PHASE3)
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma (PHASE1)
- SL4903 CAR-T Therapy for Relapsed/Refractory Multiple Myeloma (EARLY_PHASE1)
- Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)
- A Platform Study of In Vivo CAR-T for Treating Advanced Malignant Tumors Based on Target Screening (EARLY_PHASE1)
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment (NA)
- Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |